See what’s new.
Duke Inventions Return a Record $115M Revenue in FY25, Highlighting Momentum in Research Translation
OTC reports highest-ever revenue as invention disclosures rise, while Duke Capital Partners delivers its strongest investment year ever.
The Translational Matchmakers: How Technology Marketing Connects Inventors with Industry
At OTC, the Technology Marketing team plays a pivotal role in moving discoveries beyond the lab.
Hands-on workshop shows Triangle’s academic life science innovators how to build their startup in FDA regulated markets
Academics from around the Triangle brought their cutting-edge biomedical innovations to a three-day startup workshop hosted by Duke, NC State, and UNC.
restor3d Secures $38 Million in Growth Capital to Drive Expansion and Innovation in Personalized Orthopedic Solutions
Newly raised funds will allow the Duke spinout to scale its personalized orthopedic solutions, advancing 3D printing and AI technologies for improved surgical outcomes.
Uplinza® (inebilizumab-cdon) is Now the First and Only FDA-Approved Treatment for IgG4-Related Disease
Originally developed at Duke, Amgen’s UPLIZNA® secures FDA approval as the first treatment for IgG4-related disease, achieving an 87% reduction in flare risk through CD19+ B-cell targeting.
Isolere Bio by Donaldson Passes Most Significant Milestone To-Date, Announces Availability of Manufacturing-Grade IsoTag™ AAV Reagent
Isolere Bio by Donaldson, a Duke spinout, announces the launch of its manufacturing-grade IsoTag™ AAV reagent, marking a major milestone in advancing gene therapy manufacturing technologies.
Gene therapy developed at Duke to be commercialized by a local biotechnology company
A universal gene editing therapy for Pompe disease, invented in the lab of Duke Professor Dwight Koeberl, is licensed for further development by local start-up GeneVentiv.
GeneVentiv Announces Global Licensing Agreement for Universal Gene Editing Therapy for Infantile Onset and Late Onset Pompe Disease
GeneVentiv Therapeutics, a Raleigh-based gene therapy company, has taken an exclusive license to Pompe disease gene editing technology developed in the lab of Professor Dwight Koeberl (Pediatrics, SOM).
Fellow Turned Inventor Gives Glaucoma Care an Upgrade
While Gabriel and Challa iterated on the new and improved GDD, they also tapped into Duke’s innovation ecosystem resources and connected with Duke’s Office for Translation & Commercialization (OTC), Duke’s tech transfer office.